Side-by-side · Research reference
TesamorelinvsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedFlagship27/68 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
Tesamorelin
Testagen
Primary target
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Testicular tissue; proposed nuclear DNA interaction
Pathway
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
Yes — physiological pulsatility preserved
Unknown — no HPG axis data
Origin
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
02Dosage Protocols
Parameter
Tesamorelin
Testagen
Frequency
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Once daily or alternate days
Evidence basis
RCT / FDA-approvedFalutz 2007Falutz 2010
Animal mechanistic / in vitro onlyFedoreyeva 2011
Duration
12–52 weeks
VAT returns within months of stopping.
—
Reconstitution
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Sterile water or bacteriostatic saline
Timing
Empty stomach, pre-sleep preferred
—
Half-life
~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010
Modified vs native GHRH (7 min t½).
Unknown — likely minutes (short peptide)
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
—
Subcutaneous
03Metabolic / Fat Loss Evidence
Parameter
Tesamorelin
Testagen
Primary fat target
Visceral adipose tissue (VAT) — abdominal
—
Effect on lean mass
Modest lean mass preservation / slight increase
—
Effect reversibility
VAT returns within months of stopping
—
Key publication
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
—
04Side Effects & Safety
Parameter
Tesamorelin
Testagen
Injection site reaction
Erythema, pruritus, redness (common)
—
Fluid retention / Edema
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
—
IGF-1 elevation
Dose-dependent; supraphysiological levels = discontinue
—
Cancer risk
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
—
Antibody formation
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
—
GI symptoms
Nausea, diarrhea (mild, transient)
—
Injection site reactions
—
Erythema, mild irritation (potential)
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Testagen
- ·Active testicular malignancy
Relative Contraindications
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
Tesamorelin
Testagen
1. Reconstitution
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Injection site
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Needle
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.
06Stack Synergy
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality
Testagen
— no documented stacks